For further information regarding the clinical trials, please speak with your doctor or contact the Virginia Piper Cancer Institute Research Department at 612-863-8716.
Please note that while our goal is to keep this Web site as current as possible, it is possible that the status of a study may be different than what is reflected below. Please contact the Virginia Piper Cancer Institute Research Department for further information.
DCVax-Brain 020221 - currently cannot enroll new patients
A Phase II Clinical Trial Evaluating DCVax®-Brain, Autologous Dendritic Cells Pulsed with Tumor Lysate Antigen for the Treatment of Glioblastoma Multiforme
N0572
A Phase I/II Trial of Sorafenib and CCI-779 in Patients with Recurrent Glioblastoma
VPJT0401
Mechanisms of Glioma Invasion of the Brain
VPWM0701
Tissue Microarrary for Validation of a New Immunohistochemical Panel Pitutary Adenoma
N0779
Phase II Study of Vorinostat (SAHA) in Combination with Bortezomib (PS-341) in Patients with Recurrent Glioblastoma Multiforme
EMD 121974-011
Cilengitide for subjects with newly diagnosed glioblastoma multiforme and methylated MGMT gene promoter - a multicenter, open-label, controlled Phase III study, testing cilengitide in combination with standard treatment (temozolomide with concomitant radiation therapy, followed by temozolomide maintenance therapy) versus standard treatment alone (CENTRIC).
N0272
Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer
E5103
A Double-Blind Phase III Trial of Doxorubicin and Cyclophasphamide followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer
40101
Cyclophosphamide and Doxorubicin (CA 4 vs 6 cycles) versus Paclitaxel (12 weeks vs 18 weeks) as Adjuvant Therapy for Node-Negative Breast Cancer: A 2x2 Factorial Randomized Study
40302
Endorcrine Therapy With or Without Inhibition of EGF and HER2 Growth Factor Receptors: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Fulvestrant With or Without Lapatinib (GW572016) for Postmenopausal Women with Hormone Receptor Positive Advanced Breast Cancer.
B-42
A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AL in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Postitive Breast Cancer
IBCSG 24-02
A Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Premenopausal Women with Endocrine Responsive Breast Cancer (SOFT)
S0221
Phase III Trial of Continuous Schedule AC+G Vs. Q2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node-Negative Breast Cancer
S0230
Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer.
B-39
A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast Cancer.
PACCT-1
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment: The TAILORx Trial
S0500
A Randomized Phase III Trial to Test the Strategy of Changing Therapy Versus Maintaining Therapy for Metastatic Breast Cancer Patients Who Have Elevated Circulating Tumor Cell Levels at First Follow-up Assessment
B-41
A Randomized Phase III Trial of Neoadjuvant Therapy for Patients with Palpable and Operable HER2-Positive Breast Cancer Comparing the Combination of Trastuzumab Plus Lapatinib to Trastuzumab and to Lapatinib Administered with Weekly Paclitaxel Following AC Accompanied by Correlative Science Studies to Identify Predictors of Pathologic Complete Response
VPLD0702
Moleculare Evidence for the Role of Lobular Involution in Pregnancy-Associated Breast Cancer
N063D
ALTTO: Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation Study: A Randomised, Multi-centre, Open-label, Phase III Study of Adjuvant Lapatinib, Trastuzumab, Their Sequence and Their Combination in Patients with HER2/ErbB2 Positive Primary Breast Cancer
E1105
A Randomized Phase III Double-Blind Placebo-Controlled Trial of First-line Chemotherapy and Trastuzumab with or without Bevacizumab for Patients with HER-2/NEU Over-expressing Metastatic Breast Cancer
40502
A Randomized Phase III Trial of Weekly Paclitaxel Compared to Weekly Nanoparticle Albumin Bound NAB-Paclitaxel or Ixabepilone Combined with Bevacizumab as First-Line Therapy for Locally Recurrent or Metastatic Breast Cancer
The use of Wisconsin Ginseng (panax quinquefoius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
N08C1
A Phase II First-line study of a combination of pemetrexed, carboplatin and Bevacizumab in Advanced Nonsquamous NSCLC Evaluating Efficacyand Tolerability in Elderly Patients (age greater than or equal to 70 yrs) with good performance status (PS<2)
A Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers
N0147 - closed to enrollment for patients ages 70 and older
A Randomized Phase III Trial of Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) With or Without Cetuximab after Curative Resection for Patients with Stage III colon Cancer
80405
A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab, or Cetuximab (C225), or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum
S0600 - currently cannot enroll new patients
Phase III Trial of Irinotecan-Based Chemotherapy Plus Cetuximab with or without Bevacizumab as Second-Line Therapy for Patients with Metastatic Colorectal Cancer who have Progressed on Bevacizumab with either FOLFOX, OPTIMOX or XELOX
A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab, or Cetuximab (C225), or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum
S0600 - currently cannot enroll new patients
Phase III Trial of Irinotecan-Based Chemotherapy Plus Cetuximab with or without Bevacizumab as Second-Line Therapy for Patients with Metastatic Colorectal Cancer who have Progressed on Bevacizumab with either FOLFOX, OPTIMOX or XELOX
Phase III Prospective Randomized Comparison of Depot Octreotide Plus Interferon Alpha Versus Depot Octreotide Plus Bevacizumab (NSC #704865) in Advanced, Poor Prognosis Carcinoid Patients
N0543
A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma
Ancillary Laboratory Protocol for Collecting Diagnostic Material on Patients considered for ECOG Treatment Trials for Leukemia or Related Hematologic Disorders
A Phase II First-line study of a combination of pemetrexed, carboplatin and Bevacizumab in Advanced Nonsquamous NSCLC Evaluating Efficacy and Tolerability in Elderly Patients (age greater than or equal to 70 yrs) with good performance status (PS<2)
H3E-US-JHMD (Pointbreak)
Randomized, Open-Label, Phase 3 Study of Pemetrexed plus Carboplatin and Bevacizumab Followed by Maintenance Pememtrexed and Bevacizumab versus Paclitaxel plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients with Stage IIIB or IV Nonsquamous Non-Small Cell Lung Cancer
C30607
Randomized, Phase III, Placebo-Controlled Trial of Sunitinib as Maintenance Therapy in Non-Progressing Paitnets Following an Initial Four Cycles of Platinum-Based Combination Chemotherapy in Advanced, Stage IIIB/IV Non-Small Cell Lung Cancer
S0424
Molecular Epidemiology Case-Series Study of Non-Small Cell Lung Cancer in Smoking and Non-smoking Women and Men.
N0321
Phase I/II Study of PS-341 in Combination with Paclitaxel, Carboplatin, and Concurrent Thoracic Radiation Therapy for Non-small Cell Lung Cancer (NSCLC) (Phase I Component)
E1505
A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Completely Resected Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC)
E5597
Phase III Chemoprevention Trial of Selenium Supplementation in Persons With Resected Stage I Non-Small Cell Lung Cancer
N0626
Phase II Randomized Study of Pemetrexed With Sorafenib versus Pemetrexed Alone as Second-Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer
N0723 (MARVEL) - currently cannot enroll new patients
A Phase III Biomarker Vlaidation Study of Second Line Therapy in Patients with Advanced Non-small Cell Lung Cancer, Randomized to Pemetrexed Versus Erotniib (MARVEL : Marker Validation of Erlotinib in Lung Cancer)
S0424 - currently cannot enroll new patients who smoke
Molecular Epidemiology Case-Series Study of Non-Small Cell Lung Cancer in Smoking and Non-smoking Women and Men
Phase III Randomized Study for Four Weeks High Dose IFN-α2b in Stage T2b No, T3a-bN0, T4a-b No, and T1-4, N1a, 2a, 3 (Microscopic) Melanoma
N0775
A Randomized Phase II Trial of Temozolomide (TMZ) and Avastin or ABI007/Carboplatin (CBDCA) and Avastin in Patients with Unresectable Stage IV Malignant Melanoma
Ancillary Laboratory Protocol for Collecting Diagnostic Material on Patients considered for Studies of Plasma Cell Disorders
E1A06
An Intergroup Phase III Randomized Controlled Trial Comparing Melphalan, Prednisone and Thalidomide (MPT) Versus Melphalan, Prednisone and Lenalidomide (Revlimid) (MPR) in Mewly Diagnosed Multiple Myeloma Patients Who Are Not Candidates for High-Dose Therapy
E1A05
Randomized Phase III Trial of Consolidation Therapy with Bortezomib (Velcade)- Lenalidomide (Revlimid)- Dexamethasone (VRD) versus Bortezomib (Velcade)- Dexamethasone (VD) for Patients with Multiple Myeloma Who Have Completed a Dexamethasone Based Induction Regimen
S0777
A Randomized Phase III Trial of CC-5013 (lenalidomide, NSC-703813) and Low Dose Dexamethasone (LLD) versus Bortezomib (PS-341, NSC-681239), Lenalidomide and Low Dose Dexamethasone (BLLD) for Induction, in Patients with Previously Untreated Multiple Myeloma without Intent for Immediate Autologous Stem Cell Transplant
A Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy Versus Immediately Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer
E3805
CHAARTED: ChemoHormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer
E5805 - currently cannot enroll new patients
A Phase II Trial of E7389 (Halichondrin B Analog) in Patients with Metastatic Hormone Refractory Prostate Cancer
A Clinical Trial Comparing Preoperative Radiation Therapy and Capecitabine with or without Oxaliplatin with Preoperative Radiation Therapy and Continuous Intravenous Infusion (CVI) of 5-FU with or without Oxaliplatin in the Treatment of Patients with Operable Carcinoma of the Rectum.
E3204
A Phase II Study of Preoperative Radiation with Concurrent Capecitabine, Oxaliplatin, and Bevacizumab Followed by Surgery and Postoperative 5-FU, Leucovorin, Oxaliplatin (FOLFOX) and Bevacizumab in Patients with Locally Advanced Rectal Cancer
80405
A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab, or Cetuximab (C225), or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum.
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AE0005 (VEGF Trap) in Patients with Metastatic Renal Cell Carcinoma
E2804
The BeST Trial: A Randomized Phase II Study of VEGF, RAF kinase, and mTOR Combination Targeted Therapy (CTT) with Bevacizumab, Sorafenib and Temsirolimus in Advanced Renal Cell Carcinoma
E2805 - currently cannot enroll new patients
A Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib versus Sorafenib versus Placebo in Patients with Resected Renal Cell Carcinoma
A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma
Virginia Piper Cancer Institute
800 East 28th Street,
Minneapolis, MN 55407
612-863-8716
Print
Send to a Friend